VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

PROSCA/BLADDR 2020 | Second-line treatment of mHSPC

Ursula Vogl • 7 Oct 2020
PROSCA/BLADDR 2020
Genitourinary Cancer Prostate Cancer

Ursula Vogl, MD, Ente Ospedaliero Cantonale (EOC), Ticino, Switzerland, explores the difficulties of sequencing second-line therapies for metastatic hormone-sensitive prostate cancer (mHSPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ursula Vogl

1:41
Challenges and treatment advances in mHSPC
Ursula Vogl • 14 Oct 2020
1:35
Unmet needs in mHSPC
Ursula Vogl • 7 Oct 2020

Related Videos

0:57
Areas of unmet need for patients with advanced UC
Elizabeth Plimack • 7 Apr 2021
3:54
Guadecitabine + atezolizumab in mUC who have progressed after initial checkpoint inhibitor therapy
Elizabeth Plimack • 7 Apr 2021
2:15
Key findings on atezolizumab for mUC from IMvigor130
Enrique Grande • 6 Apr 2021
3:12
IMvigor130: OS data for atezolizumab plus chemo versus chemo alone
Enrique Grande • 6 Apr 2021
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals